Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$107.26 USD

107.26
8,540,923

+3.34 (3.21%)

Updated Jul 24, 2024 04:00 PM ET

After-Market: $107.14 -0.12 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Products

Better trading starts here.

Balance Sheet

Research for ABT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Abbott Laboratories falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 7,279 10,170 10,249 7,148 4,140
Receivables 6,565 6,218 6,487 6,414 5,425
Notes Receivable 0 0 0 0 0
Inventories 6,570 6,173 5,157 5,012 4,316
Other Current Assets 2,256 2,663 2,346 1,867 1,786
Total Current Assets 22,670 25,224 24,239 20,441 15,667
Net Property & Equipment 10,154 9,162 8,959 9,029 8,038
Investments & Advances 799 766 816 821 883
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 7,097 6,033 5,212 3,729 3,079
Intangibles 32,494 33,253 35,970 38,528 40,220
Deposits & Other Assets 0 0 0 0 0
Total Assets 73,214 74,438 75,196 72,548 67,887
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 213 201
Accounts Payable 4,295 4,607 4,408 3,946 3,252
Current Portion Long-Term Debt 1,080 2,251 754 7 1,277
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 7,019 7,401 6,806 6,581 5,272
Income Taxes Payable 492 343 306 362 226
Other Current Liabilities 955 887 831 798 635
Total Current Liabilities 13,841 15,489 13,105 11,907 10,863
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 13,599 14,522 17,296 18,527 16,661
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 6,947 7,522 8,771 9,111 9,062
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 34,387 37,533 39,172 39,545 36,586
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 24,869 24,709 24,470 24,145 23,853
Capital Surplus 0 0 0 0 0
Retained Earnings 37,554 35,257 31,528 27,627 25,847
Other Equity -7,615 -7,832 -8,152 -8,727 -8,252
Treasury Stock 15,981 15,229 11,822 10,042 10,147
Total Shareholder's Equity 38,827 36,905 36,024 33,003 31,301
Total Liabilities & Shareholder's Equity 73,214 74,438 75,196 72,548 67,887
Total Common Equity 38,827 36,905 36,024 33,003 31,301
Shares Outstanding 1,736.00 1,743.50 1,768.20 1,772.30 1,768.40
Book Value Per Share 22.37 21.17 20.37 18.62 17.70

Fiscal Year End for Abbott Laboratories falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 6,651 7,279 7,047 8,155
Receivables NA 6,605 6,565 6,499 6,172
Notes Receivable NA 0 0 0 0
Inventories NA 6,827 6,570 6,650 6,871
Other Current Assets NA 2,293 2,256 2,468 2,307
Total Current Assets NA 22,376 22,670 22,664 23,505
Net Property & Equipment NA 10,107 10,154 9,552 9,449
Investments & Advances NA 818 799 788 799
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 7,487 7,097 6,527 6,509
Intangibles NA 31,679 32,494 32,559 33,092
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 72,467 73,214 72,090 73,354
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 4,178 4,295 3,961 4,211
Current Portion Long-Term Debt NA 2,010 1,080 1,051 2,284
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 6,312 7,019 6,826 6,696
Income Taxes Payable NA 562 492 318 273
Other Current Liabilities NA 959 955 886 886
Total Current Liabilities NA 14,021 13,841 13,042 14,350
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 12,576 13,599 14,477 14,562
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 6,947 6,877 7,038
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 33,424 34,387 34,396 35,950
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 24,726 24,869 24,727 24,612
Capital Surplus NA 0 0 0 0
Retained Earnings NA 38,011 37,554 36,920 36,355
Other Equity NA -7,933 -7,615 -8,267 -7,841
Treasury Stock NA 15,761 15,981 15,686 15,722
Total Shareholder's Equity NA 39,043 38,827 37,694 37,404
Total Liabilities & Shareholder's Equity NA 72,467 73,214 72,090 73,354
Total Common Equity 0 39,043 38,827 37,694 37,404
Shares Outstanding 1,739.60 1,739.60 1,736.00 1,736.00 1,735.30
Book Value Per Share 0.00 22.44 22.37 21.71 21.55